D Jay McCracken1, Jon T Willie1,2,3, Brad A Fernald4, Amit M Saindane5, Daniel L Drane6, Daniel L Barrow1, Robert E Gross1,2,3,7. 1. Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia. 2. Department of Neurology, Emory University School of Medicine, Atlanta, Georgia. 3. Interventional MRI Program, Emory University Hospital, Atlanta, Georgia. 4. Visualase, Inc., Houston, Texas. 5. Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia. 6. Department of Neurology, University of Washington School of Medicine, Seattle, Washington. 7. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia.
Abstract
BACKGROUND: Surgery is indicated for cerebral cavernous malformations (CCM) that cause medically refractory epilepsy. Real-time magnetic resonance thermography (MRT)-guided stereotactic laser ablation (SLA) is a minimally invasive approach to treating focal brain lesions. SLA of CCM has not previously been described. OBJECTIVE: To describe MRT-guided SLA, a novel approach to treating CCM-related epilepsy, with respect to feasibility, safety, imaging, and seizure control in 5 consecutive patients. METHODS: Five patients with medically refractory epilepsy undergoing standard presurgical evaluation were found to have corresponding lesions fulfilling imaging characteristics of CCM and were prospectively enrolled. Each underwent stereotactic placement of a saline-cooled cannula containing an optical fiber to deliver 980-nm diode laser energy via twist drill craniostomy. MR anatomic imaging was used to evaluate targeting prior to ablation. MR imaging provided evaluation of targeting and near real-time feedback regarding extent of tissue thermocoagulation. Patients maintained seizure diaries, and remote imaging (6-21 months post-ablation) was obtained in all patients. RESULTS: Imaging revealed no evidence of acute hemorrhage following fiber placement within presumed CCM. MRT during treatment and immediate post-procedure imaging confirmed desired extent of ablation. We identified no adverse events or neurological deficits. Four of 5 (80%) patients achieved freedom from disabling seizures after SLA alone (Engel class 1 outcome), with follow-up ranging 12-28 months. Reimaging of all subjects (6-21 months) indicated lesion diminution with surrounding liquefactive necrosis, consistent with the surgical goal of extended lesionotomy. CONCLUSION: Minimally invasive MRT-guided SLA of epileptogenic CCM is a potentially safe and effective alternative to open resection. Additional experience and longer follow-up are needed.
BACKGROUND: Surgery is indicated for cerebral cavernous malformations (CCM) that cause medically refractory epilepsy. Real-time magnetic resonance thermography (MRT)-guided stereotactic laser ablation (SLA) is a minimally invasive approach to treating focal brain lesions. SLA of CCM has not previously been described. OBJECTIVE: To describe MRT-guided SLA, a novel approach to treating CCM-related epilepsy, with respect to feasibility, safety, imaging, and seizure control in 5 consecutive patients. METHODS: Five patients with medically refractory epilepsy undergoing standard presurgical evaluation were found to have corresponding lesions fulfilling imaging characteristics of CCM and were prospectively enrolled. Each underwent stereotactic placement of a saline-cooled cannula containing an optical fiber to deliver 980-nm diode laser energy via twist drill craniostomy. MR anatomic imaging was used to evaluate targeting prior to ablation. MR imaging provided evaluation of targeting and near real-time feedback regarding extent of tissue thermocoagulation. Patients maintained seizure diaries, and remote imaging (6-21 months post-ablation) was obtained in all patients. RESULTS: Imaging revealed no evidence of acute hemorrhage following fiber placement within presumed CCM. MRT during treatment and immediate post-procedure imaging confirmed desired extent of ablation. We identified no adverse events or neurological deficits. Four of 5 (80%) patients achieved freedom from disabling seizures after SLA alone (Engel class 1 outcome), with follow-up ranging 12-28 months. Reimaging of all subjects (6-21 months) indicated lesion diminution with surrounding liquefactive necrosis, consistent with the surgical goal of extended lesionotomy. CONCLUSION: Minimally invasive MRT-guided SLA of epileptogenic CCM is a potentially safe and effective alternative to open resection. Additional experience and longer follow-up are needed.
Authors: Alexandre Carpentier; Roger J McNichols; R Jason Stafford; Jean-Pierre Guichard; Daniel Reizine; Suzette Delaloge; Eric Vicaut; Didier Payen; Ashok Gowda; Bernard George Journal: Lasers Surg Med Date: 2011-11-22 Impact factor: 4.025
Authors: Pinakin R Jethwa; Jason H Lee; Rachid Assina; Irwin A Keller; Shabbar F Danish Journal: J Neurosurg Pediatr Date: 2011-11 Impact factor: 2.375
Authors: Alexandre Carpentier; Roger J McNichols; R Jason Stafford; Julian Itzcovitz; Jean-Pierre Guichard; Daniel Reizine; Suzette Delaloge; Eric Vicaut; Didier Payen; Ashok Gowda; Bernard George Journal: Neurosurgery Date: 2008-07 Impact factor: 4.654
Authors: Robert E Gross; Matthew A Stern; Jon T Willie; Rebecca E Fasano; Amit M Saindane; Bruno P Soares; Nigel P Pedersen; Daniel L Drane Journal: Ann Neurol Date: 2018-03-03 Impact factor: 10.422
Authors: Eric Prince; Shahin Hakimian; Andrew L Ko; Jeffrey G Ojemann; Michelle S Kim; John W Miller Journal: Curr Neurol Neurosci Rep Date: 2017-09 Impact factor: 5.081
Authors: Jon T Willie; James G Malcolm; Matthew A Stern; Lindsay O Lowder; Stewart G Neill; Brian T Cabaniss; Daniel L Drane; Robert E Gross Journal: Epilepsia Date: 2019-01-17 Impact factor: 5.864